Table 6 Proportion of participants with a 4-fold or greater increase from baseline-PP analyses
Arm | Month 1 n (%) | Month 2 n (%) | Month 3 n (%) | Month 6 n (%) |
|---|---|---|---|---|
C-Term | ||||
Group 1 | 47/47 (100) | 50/50 (100) | 49/49 (100) | 48/48 (100) |
Group 2 | 48/49 (98) | 48/48 (100) | 48/48 (100) | 48/48 (100) |
Group 3 | 2/18 (11) | 4/19 (21) | 6/18 (33) | 1/18 (6) |
NANP6 | ||||
Group 1 | 50/50 (100) | 50/50 (100) | 50/50 (100) | 48/48 (100) |
Group 2 | 50/50 (100) | 50/50 (100) | 49/49 (100) | 48/48 (100) |
Group 3 | 2/20 (10) | 4/20 (20) | 5/20 (25) | 2/20 (10) |
Full length R21 | ||||
Group 1 | 45/45 (100) | 48/48 (100) | 48/48 (100) | 46/46 (100) |
Group 2 | 47/47 (100) | 47/47 (100) | 46/46 (100) | 45/45 (100) |
Group 3 | 6/18 (33) | 3/18 (17) | 6/18 (33) | 3/16 (19) |
Hepatitis B surface antigen | ||||
Group 1 | 15/48 (31) | 14/47 (30) | 30/48 (63) | 17/47 (36) |
Group 2 | 13/49 (27) | 20/49 (41) | 33/49 (67) | 18/48 (38) |
Group 3 | 0/20 (0) | 0/20 (0) | 0/20 (0) | 1/20 (5) |
